Open Access Repository

Thiazolidinedione use is associated with reduced risk of Parkinson's disease in patients with diabetes: a meta-analysis of real-world evidence

Hussain, S, Singh, A, Baxi, H, Taylor, B, Burgess, J ORCID: 0000-0003-4748-9571 and Antony, B ORCID: 0000-0001-8704-6084 2020 , 'Thiazolidinedione use is associated with reduced risk of Parkinson's disease in patients with diabetes: a meta-analysis of real-world evidence' , Neurological Sciences , pp. 1-7 , doi: 10.1007/s10072-020-04494-3.

Full text not available from this repository.

Abstract

Background: The thiazolidinedione (TZD) class of oral antidiabetic agents are used to treat type 2 diabetes mellitus (DM). This meta-analysis aimed to understand the protective effect of TZD on Parkinson's disease (PD) in people with diabetes. Method: A literature search was performed in PubMed, Embase, and Cochrane central from inception to until 30 September 2019. We included all real-world evidence studies assessing the use of TZD class of drugs and the risk of PD in people with diabetes. Quality of the studies was evaluated using the Newcastle-Ottawa scale. The primary outcome was the pooled hazard ratio (HR) of PD among type 2 DM TZD users as compared with TZD non-users in people with diabetes. The secondary outcome was the HR of PD among type 2 DM TZD users as compared with non-users (include both diabetic and nondiabetic population). Meta-analysis was performed using RevMan software. Results: Out of five studies selected for inclusion, four studies fulfilled the criteria for primary outcomes. The participants' mean age and follow-up duration were 66.23 ± 9.59 years and 5.25 years (2.97-7.9 years), respectively. There was a significant reduction in the risk of PD (pooled adjusted HR of 0.81 [95% CI 0.70-0.93, p = 0.004]) in TZD users compared with non-TZD users in people with diabetes. A significant protective effect of TZD was observed in Caucasian population (3 studies) (HR 0.78 (95% CI 0.66-0.92), p = 0.003). Conclusion: This meta-analysis demonstrates a potential neuroprotective effect of TZD for PD risk in the population with DM.

Item Type: Article
Authors/Creators:Hussain, S and Singh, A and Baxi, H and Taylor, B and Burgess, J and Antony, B
Keywords: diabetes mellitus, glitazone, Parkinson's disease, pioglitazone, thiazolidinedione's, meta-analysis
Journal or Publication Title: Neurological Sciences
Publisher: Springer-Verlag
ISSN: 1590-1874
DOI / ID Number: 10.1007/s10072-020-04494-3
Copyright Information:

Copyright 2020 Fondazione Società Italiana di Neurologia

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page
TOP